Fox Williams Advises Clywedog Therapeutics in Proposed Merger with Barinthus Biotherapeutics

Fox Williams advised Clywedog Therapeutics, Inc., a private biotechnology company advancing novel therapies in metabolic and autoimmune diseases, on the UK aspects of its proposed merger with Barinthus Biotherapeutics plc (NASDAQ: BRNS), an immunology and inflammation company focused on promoting immune tolerance.

The all-stock transaction will create a combined company advancing a portfolio of clinical-stage candidates for Type 1 and Type 2 diabetes as well as celiac disease.

The combined company, which will operate under the name Clywedog Therapeutics, Inc., is expected to trade on NASDAQ under the ticker symbol “CLYD.” Four key value-driving clinical milestones are anticipated within 18 months, with an estimated cash runway extending through 2027.

The transaction, which was announced on 30 September 2025 is projected to close in the first half of 2026 and will be supported by existing investors as well as additional investments from OrbiMed and Torrey Pines Investment LLC.

Corporate partner Richie Clark led the Fox Williams team, which also included corporate associate Anjali Aravindhan, head of tax and incentives Emma Bailey, tax senior associate Kaleem Khan and employment partner David Murphy.

Fox Williams worked in close cooperation with US firm Snell & Wilmer on the transaction.